Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 17 for:    Givinostat

Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00928707
Recruitment Status : Completed
First Posted : June 26, 2009
Results First Posted : October 31, 2019
Last Update Posted : October 31, 2019
Sponsor:
Information provided by (Responsible Party):
Italfarmaco

Brief Summary:

The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy.

The secondary objectives of this study were:

  • To evaluate the safety and tolerability of Givinostat in combination with hydroxyurea in patients with JAK2V617Fpositive PV non-responders to the maximum tolerated dose of hydroxyurea monotherapy;
  • To explore the impact in terms of efficacy and tolerability of Givinostat 50 mg dose escalation in patients not achieving at least a partial response at the time when the primary endpoint was assessed (week 12);
  • To evaluate the molecular response (JAK2 mutated allele burden) by quantitative Real Time-Polymerase Chain Reaction (RT-PCR);
  • To evaluate the reduction of the fraction of JAK2V617F positive clonogenic progenitors.

Condition or disease Intervention/treatment Phase
Polycythemia Vera Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea Phase 2

Detailed Description:

This is a multicentre, randomized, open-label, phase II study testing GIVINOSTAT (ITF2357) in combination with hydroxyurea in a population of patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.

Recruited patients will be randomly assigned to one of the following treatment groups:

  • group A: 50 mg o.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum tolerated dose of hydroxyurea monotherapy already in use before admission to the study;
  • group B: 50 mg b.i.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum tolerated dose of hydroxyurea monotherapy already in use before admission to the study.

The two groups will be balanced for number and for Centre in order to provide valuable information on both treatment regimens.

In both groups assigned doses shall remain stable until week 12, which is when the primary endpoint is assessed, unless specific tolerability issues arise which impose dose reduction.

After the primary endpoint assessment at week 12, one of the following treatment schedules will be chosen case by case on the basis of the achieved clinical response and continued for up to 12 further weeks:

  • Partial or Complete Response at week 12:
  • group A: continue 50 mg o.d.;
  • group B: continue 50 mg b.i.d.;
  • No Response at week 12:
  • group A: increase to 50 mg b.i.d.;
  • group B: increase to 50 mg t.i.d.. At any time during study course, if toxicity is observed, GIVINOSTAT (ITF2357) treatment will be discontinued until recovery and then restarted at a reduced dose level. The drug will be definitively withdrawn in case of reappearance of toxicity even at a reduced daily dose. Overall, the treatment will last up to a maximum of 24 cumulative weeks of drug administration.

The study will recruit subjects of both genders with an established diagnosis of JAK2V617F positive Polycythemia Vera according to the revised WHO criteria, in need of cytoreductive therapy, non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of the Histone-deacetylase Inhibitor GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Patients With JAK2V617F Positive Polycythemia Vera Non-responder to Hydroxyurea Monotherapy.
Study Start Date : June 2009
Actual Primary Completion Date : July 2011
Actual Study Completion Date : October 2011


Arm Intervention/treatment
Experimental: GIVINOSTAT + MTD Hydroxyurea (HU)_1
50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea
50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
Other Names:
  • GIVINOSTAT (ITF2357)
  • ONCOCARBIDE (HYDROXYUREA)

Experimental: GIVINOSTAT + MTD Hydroxyurea (HU)_2
50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
Other Names:
  • GIVINOSTAT (ITF2357)
  • ONCOCARBIDE (HYDROXYUREA)




Primary Outcome Measures :
  1. Percentage of Patients With Overall Haematological Response at Week 12. [ Time Frame: At week 12 of treatment ]
    The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) < 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT < 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.


Secondary Outcome Measures :
  1. Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12. [ Time Frame: At week 24 of treatment ]

    Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12).

    • Complete response:

      1. HCT< 45% without phlebotomy, and
      2. platelets ≤ 400 x109/L, and
      3. WBC ≤ 10 x 109/L, and
      4. no splenomegaly, and
      5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache);
    • Partial response:

      1. HCT < 45% without phlebotomy, or
      2. fulfilment of at least 3 of the other above mentioned criteria;
    • No response:

    any response that did not satisfy the criteria set for partial response.


  2. Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR [ Time Frame: At weeks 12, 24, at "drop out visit" and at "End of Study" (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24. ]
    To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs).

  3. Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints [ Time Frame: Baseline, at weeks 12 and 24 ]

    JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks).

    Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid)




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written Informed Consent.
  • Age ≥18 years.
  • Confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization (WHO) criteria.
  • JAK2V617F positivity.
  • Non-response to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.
  • ECOG (Eastern Cooperative Oncology Group) performance status <3.
  • Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential.
  • Willingness and capability to comply with the requirements of the study.

Exclusion Criteria:

  • Active bacterial or mycotic infection requiring antimicrobial treatment.
  • Pregnancy or lactation.
  • A marked baseline prolongation of QT/QTc (corrected) interval (e.g. repeated demonstration of a QTc interval > 450 ms, according to Bazett's correction formula).
  • Use of concomitant medications that prolong the QT/QTc interval.
  • Clinically significant cardiovascular disease including:

    • Uncontrolled hypertension, myocardial infarction, unstable angin, within 6 months from study start;
    • New York Heart Association (NYHA) Grade II or greater congestive heart failure;
    • History of any cardiac arrhythmia requiring medication (irrespective of its severity);
    • A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Positive blood test for HIV (Human Immunodeficiency Virus)
  • Active HBV (Hepatitis B Virus) and/or HCV (Hepatitis C Virus) infection.
  • Platelets count <100x109/L within 14 days before enrolment.
  • Absolute neutrophil count <1.2x109/L within 14 days before enrolment.
  • Serum creatinine >2xULN (upper limit of normal).
  • Total serum bilirubin >1.5xULN.
  • Serum aspartate aminotransferase (AST) / alanine aminotransferase (ALT) > 3xULN.
  • History of other diseases, metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications.
  • Interferon alpha within 14 days before enrolment.
  • Anagrelide within 7 days before enrolment.
  • Any other investigational drug within 28 days before enrolment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00928707


Locations
Show Show 22 study locations
Sponsors and Collaborators
Italfarmaco
Investigators
Layout table for investigator information
Principal Investigator: Alessandro Rambaldi, MD Azienda Ospedaliera Ospedali Riuniti di Bergamo
Layout table for additonal information
Responsible Party: Italfarmaco
ClinicalTrials.gov Identifier: NCT00928707    
Other Study ID Numbers: DSC/08/2357/38
First Posted: June 26, 2009    Key Record Dates
Results First Posted: October 31, 2019
Last Update Posted: October 31, 2019
Last Verified: October 2019
Keywords provided by Italfarmaco:
Polycythemia Vera
GIVINOSTAT
ITF2357
Additional relevant MeSH terms:
Layout table for MeSH terms
Givinostat hydrochloride
Polycythemia Vera
Polycythemia
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Bone Marrow Diseases
Myeloproliferative Disorders
Hydroxyurea
Antineoplastic Agents
Antisickling Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Histone Deacetylase Inhibitors